SEC Tracker
Get the app

NextCure NXTC

NextCure announces Q3 2026 financial results

NextCure (NXTC) filed an 8-K with the SEC on Nov 10, 2026, 4:15 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities as of September 30, 2026 were $8.7 million
  2. Research and development expenses were $4.5 million for the three months ended September 30, 2026
  3. Financing commitments supporting the Merger increased to approximately $820 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when NextCure files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.